Long-term results of CCG 5942: A randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma - A report from the Children's Oncology Group

Journal of Clinical Oncology

Volumn 30, Issue 26, 2012, Pages 3174-3180

  Wolden, Suzanne L ^a   Chen, Lu ^c   Kelly, Kara M ^b   Herzog, Philip ^d   Gilchrist, Gerald S ^e   Thomson, John ^f   Sposto, Richard ^c   Kadin, Marshall E ^g   Hutchinson, Raymond J ^h   Nachman, James ⁱ  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

^e MAYO CLINIC   (United States)

^f PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h Scottish Rite Hospital   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GALLIUM; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHILD; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; EVENT FREE SURVIVAL; FOLLOW UP; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LONG TERM CARE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SECONDARY LEUKEMIA; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; MALE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84866559361     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.1819     Document Type: Article

References (19)

1. Schwartz CL, Constine LS, Villaluna D, et al: A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate and high-risk Hodgkin lymphoma: The results of P9425. Blood 114:2051-2059, 2009
2. Tebbi CK, Mendenhall N, London WB, et al: Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: A Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 46:198-202, 2006 (Pubitemid 43076071)
3. Donaldson SS, Link MP, Weinstein HJ, et al: Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 25:332-337, 2007 (Pubitemid 350003023)
4. Dörffel W, Lüders H, Rühl U, et al: Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: Analysis and outlook. Klin Padiatr 215:139-145, 2003 (Pubitemid 36718285)
5. Kelly KM, Sposto R, Hutchinson RJ, et al: BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: A report from the Children's Oncology Group. Blood 117:2596-2603, 2011
6. Nachman JB, Sposto R, Herzog P, et al: Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20:3765-3771, 2002
7. Wolden SL, Lamborn KR, Cleary SF, et al: Second cancers following pediatric Hodgkin's disease. J Clin Oncol 16:536-544, 1998 (Pubitemid 28135596)
8. Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 11:1208-1215, 1993 (Pubitemid 23199121)
9. Mulrooney DA, Yeazel MW, Kawashima T, et al: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606, 2009
10. O'Brien MM, Donaldson SS, Whittemore MP, et al: Second malignant neoplasms among survivors of pediatric Hodgkin disease treated with low-dose radiation (15-25.5 Gy) and chemotherapy. J Clin Oncol 27:519s, 2009 (suppl; abstr 10003)
11. Harris RE, Termuhlen AM, Smith LM, et al: Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: Results of Children's Oncology Study Group A5862. Biol Blood Marrow Transplant 17:249-258, 2011
12. Castellino SM, Geiger AM, Mertens AC, et al: Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study. Blood 117:1806-1816, 2011
13. Bowers DC, McNeil DE, Liu Y, et al: Stroke as a late effect of Hodgkin's disease: A report from the Childhood Cancer Survivor Study. J Clin Oncol 23:6508-6515, 2005 (Pubitemid 46190242)
14. Friedman DL, Whitton J, Leisenring W, et al: Subsequent neoplasms in 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl Cancer Inst 102:1083-1095, 2010
15. Hutchinson RJ, Fryer CJ, Davis PC, et al: MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: Results of the Children's Cancer Group phase III trial. J Clin Oncol 16:897-906, 1998 (Pubitemid 28108721)
16. Chen RC, Chin MS, Ng AK, et al: Earlystage, lymphocyte-predominant Hodgkin's lymphoma: Patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 28:136-141, 2010
17. Gallamini A, Hutchings M, Rigacci L, et al: Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007 (Pubitemid 47372616)
18. Hutchings M, Loft A, Hansen M, et al: FDGPET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59, 2006 (Pubitemid 43053523)
19. Friedman DL, Wolden S, Constine K, et al: AHPD0031: A phase III study of dose-intensive therapy for intermediate risk Hodgkin lymphoma-A report from the Children's Oncology Group. Blood 116:766, 2010 (abstr)